Angiex selected ZingPR to generate excitement and build momentum for the Phase 1 clinical trial of AGX101, a novel antibody-drug conjugate (ADC) designed to revolutionize cancer treatment by targeting tumor blood vessels. The campaign played a crucial role in communicating the potential of AGX101 to transform cancer treatment and attracting support for Angiex's mission.

ZingPR helped Transform Materials, a Florida-based deeptech startup, announce a groundbreaking collaboration with Johnson Matthey that's set to revolutionize the PVC industry. Our strategic media outreach focused on highlighting the partnership's environmental benefits, scalability, and industry-leading expertise.

In the world of science PR, it's not enough to have groundbreaking research – you need a story that grips. A narrative that not only informs but also intrigues. So how do you break through the clutter and make your science news sing?

Launching a new robotics solution is always a challenge. It's highly technical and can be difficult to translate for a general audience. That's why OSARO partnered with ZingPR to craft a compelling media strategy. Instead of focusing on specs, we highlighted the real-world benefits: warehouse safety and efficiency.

rBIO's biosimilar insulin story landed in Wired, MedCity News, and more. See the PR tactics that drove success and get tips for your biotech launch.

CureLab Oncology’s DNA vaccine Elenagen, in combination with a proven chemotherapy, demonstrates promising clinical results against one of the deadliest forms of ovarian cancer.

Gero is a cutting-edge biotechnology company dedicated to the mission of curing age-related human diseases and understanding, slowing, and even halting the aging process itself.

Cyclica will apply its AI-enabled drug discovery platform to discover new therapeutic options with the goal of expanding the range of accessible non-hormonal contraceptive choices for women in developing countries.

Two biotech leaders have embarked on a research project to streamline manufacturing of non-viral CRISPR gene editing components. Their goal is to improve the editing efficiency and cell viability of non-viral-based cell therapies.

The clinical benefits currently delivered for terminally ill patients in CureLab’s clinical trial are already exceeding the benefits of new drugs recently approved by the FDA.

LumaPay™ enables patients to pay their bills right from text messages or their providers' websites. The announcement is part of a broader repositioning of Luma's focus on patient success.

GenScript’s new GMP-grade GenExact™ single-stranded DNA (ssDNA) and GenWand™ closed-end linear double-stranded DNA (dsDNA) services enable new workflows

Allelica and Invitae want to integrate lifesaving genomic information into breast cancer risk assessments — for the benefit all women

Opalia hits a key go-to-market milestone by eliminating fetal bovine serum from its cell-based milk manufacturing process

Allelica, the leader in Polygenic Risk Scoring, expands scientific advisory board

INNOTECH and OSARO collaborate to build a demonstration AI-powered picking-robot system for Rohto Pharmaceutical’s next-generation smart factory